Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Daily News

Year in Review: Evidence Around AI in Cardiology Grows

Todd Neale

December 23, 2025

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

L.A. McKeown

October 15, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News CRT 2019

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Yael L. Maxwell

March 03, 2019

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Michael O'Riordan

June 14, 2016

News Daily News

FDA Advisory Committee Rejects AngelMed Guardian Intracardiac Monitor

Todd Neale

March 17, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Shelley Wood

January 18, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Todd Neale

June 29, 2015

News Daily News

Ticagrelor Pretreatment May Help Protect Against Periprocedural Myonecrosis in NSTE-ACS

June 04, 2015

Advertisement

Year in Review: Evidence Around AI in Cardiology Grows

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Implantable Cardiac Monitor May Reduce Delays to Hospital in High-Risk ACS

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

FDA Advisory Committee Rejects AngelMed Guardian Intracardiac Monitor

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Ticagrelor Pretreatment May Help Protect Against Periprocedural Myonecrosis in NSTE-ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content